3rd Quarter - Report

CEPHEID for CEPHEID

Firm
Client
Income
—
Expenses
$40,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

See page three Lobbying Issues: molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues HR 436/ S 17, Protect Medical Innovation Act of 2011 HR 488, Save Our Medical Devices Act of 2011 HR 755, Investing in Our Future Act of 2011 HR 965/ S 1211, Preservation of Antibiotics for Medical Treatment Act of 2011 HR 2182 Generating Antibiotic Incentives Now (GAIN) S 660, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services (PATIENTS) Act of 2011

LobbyistCovered position, as disclosed
HALLIE CHRISTINE LEWIS —
MICHELE M SCHOONMAKER —

Contacted: Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); SENATE; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Agency for Healthcare Research & Quality (AHRQ)

Bills named: H.R. 755 (112th), H.R. 488 (112th), H.R. 436 (112th), H.R. 965 (112th), H.R. 2182 (112th)

Medicare/Medicaid MMM

See page 7 Lobbying Issues: molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues HR 436/ S 17, Protect Medical Innovation Act of 2011 HR 488, Save Our Medical Devices Act of 2011 HR 755, Investing in Our Future Act of 2011 HR 965/ S 1211, Preservation of Antibiotics for Medical Treatment Act of 2011 HR 2182 Generating Antibiotic Incentives Now (GAIN) S 660, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services (PATIENTS) Act of 2011

LobbyistCovered position, as disclosed
HALLIE CHRISTINE LEWIS —
MICHELE M SCHOONMAKER —

Contacted: Natl Institutes of Health (NIH); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 436 (112th), H.R. 755 (112th), H.R. 965 (112th), H.R. 2182 (112th), H.R. 488 (112th)

Medical/Disease Research/Clinical Labs MED

See page five Lobbying Issues: molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues HR 436/ S 17, Protect Medical Innovation Act of 2011 HR 488, Save Our Medical Devices Act of 2011 HR 755, Investing in Our Future Act of 2011 HR 965/ S 1211, Preservation of Antibiotics for Medical Treatment Act of 2011 HR 2182 Generating Antibiotic Incentives Now (GAIN) S 660, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services (PATIENTS) Act of 2011

LobbyistCovered position, as disclosed
HALLIE CHRISTINE LEWIS —
MICHELE M SCHOONMAKER —

Contacted: Centers For Disease Control & Prevention (CDC); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ)

Bills named: H.R. 488 (112th), H.R. 2182 (112th), H.R. 436 (112th), H.R. 755 (112th), H.R. 965 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.